oliver zhong

Oliver Zhong

Partner (Linklaters LLP, England & Wales), New Economy Team Leader (Greater China), Registered Foreign Lawyer (New York), Hong Kong SAR

“Innovation is the fountain of economic growth and social change. For over 15 years, I have focused on helping innovative companies raise capital from public markets through transformative milestones such as IPOs and bond issues. I take pride in being a trusted adviser for my clients as they navigate these critical phases and emerge as better companies.”

Overview

Education and qualifications

Published works

Overview

Oliver is a well reputed capital markets lawyer with extensive experience advising multinational and Chinese corporates and financial institutions on significant corporate finance transactions, including Hong Kong and U.S.-registered initial public offerings and debt offerings under Rule 144A and Regulation S, with a focus on issuers in “New Economy” sectors including healthcare, tech and consumer industries. Oliver is recognised as a Notable Practitioner in Hong Kong equity capital markets by IFLR 2023.

Work highlights

Highlights* of Oliver’s practice include:

  • Deep IPO experience across the New Economy
  • Healthcare: Qyuns Therapeutics (first HK-listed biotech exclusively focused on immunology), MicroPort MedBot, MicroPort NeuroTech and MicroPort CRM (proposed)(carve-outs from HK-listed MicroPort Scientific Corporation), Ocumension Therapeutics (first HK-listed biotech specialized in ophthalmology), Zhaoke Ophthalmology, and Shanghai Henlius Biotech (dual-level spin-off from HK-listed Fosun International and HK- and Shanghai-listed Fosun Pharma).*
  • TMT and consumer: Chifeng Gold, Minieye Technology, YH Entertainment, UBOX Online, Youran Dairy, Babytree and SouFun.
  • Notable IPOs in other industries: Chery Auto, SANY Heavy Industry, ManpowerGroup Greater China (carve-out from NYSE-listed ManpowerGroup), Sunshine 100 China Holdings and PanAsialum Holdings.*
  • Equity-linked transactions: Alibaba Group’s US$3.2bn convertible bonds (largest CB issuance globally in 2025) and HK$12.023bn exchangeable bonds into Ali Health ; convertible bond offerings by Viva Biotech Holdings.*
  • Over 130 Rule 144A and Regulation S “high yield” debt offerings, including those conducted by CAR Inc., Guangzhou R&F, Shimao Property, Hilong Holding, CIFI Holdings, Modern Land China, Longfor Properties, SOHO China, China Oil & Gas Group and China Logistics Property Holdings.*
  • Investment-grade, “cov lite” debt offerings, including all offshore bonds by Fosun International, Fosun High Technology’s RMB1 billion 4.90% notes due 2028 (first “Yulan Bond” issued by a private company), Haidilao International Holding’s landmark debut offering of US$600 million 2.150% notes due 2026 (first global bond offering by a Chinese catering company), and offerings by Tingyi Holding (Master Kang) and Golden Eagle Retail Group.*
  • Exchange and tender offers and consent solicitations, including Fosun International, Guangzhou R&F, Hilong Holding, Modern Land China, China Fortune Land Development and Kaisa Group.*
  • Offshore restructuring, including Hilong Holding’s restructuring of its offshore U.S. dollar–denominated notes through a scheme of arrangement in the Cayman Islands (the first completed offshore restructuring in the PRC oil and gas sector).*

*Denotes experience from previous firm

Education and qualifications

  • University of Michigan Law School, J.D., 2008 
  • University of Texas at Austin, M.P.A., 2004 
  • Shanghai International Studies University, LL.B., 2002

Oliver speaks fluent English and Mandarin.

 

 

Published works

Oliver authored an article entitled “Dawn of a New Constitutional Era or Opportunity Wasted? An Intellectual Reappraisal of China’s Anti-Monopoly Law” in the Columbia Journal of Asian Law, 2010.